{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"sCR"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"CR"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"VGPR"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"PR"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"title":"MR"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"title":"SD"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"title":"PD"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}],"title":"NE (not evaluable)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Per EBMT: CR, negative immunofixation of serum and urine, disappearance of plasmacytomas and \\< 5% plasma cells; Stringent complete response (SCR), CR + normal flow cytometry and absence of clonal plasma cells; Very good partial response (VGPR), Serum and urine M-protein detectable on immunofixation but not on electrophoresis or \\> 90% reduction is serum and urine M protein; Partial response (PR), \\> 50% reduction in serum M-protein and \\> 90% reduction in 24 hour urine M-protein, \\> 50% reduction in baseline soft tissue plasmacytoma; Minimal response (MR), 25-49% reduction of serum M-protein and 50-59% reduction in 24 hour urine M-protein, 25-49% reduction in plasmacytomas and no increase in lytic bone lesions; Stable disease (SD), not meeting criteria for CR, VGPR, MR, PR or progressive disease (PD); PD, increase of 25% or more from nadir in serum M-protein, urine M-protein, new or increased bone lesions or plasmacytomas, or hypercalcemia solely attributed to multiple myeloma.","groups":[{"description":"Acalabrutinib 100 mg twice daily (bid) continuously","id":"OG000","title":"Cohort 1"},{"description":"Acalabrutinib 100 mg bid continuously and 40 mg dexamethasone once weekly","id":"OG001","title":"Cohort 2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From first dose of study drug up to Cycle 12 (48 weeks). Subjects who showed benefit from study drugs were allowed to continue until disease progression","title":"Response Assessed According to Guidelines Proposed by the International Myeloma Workshop Consensus Panel and European Group for Blood and Marrow Transplant","type":"SECONDARY","unitOfMeasure":"Participants"}